FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development
Decision brief
Answer first · skim in under a minute
The FDA has issued final guidance to assist sponsors in developing new antibacterial drugs for pulmonary tuberculosis. This guidance finalizes a draft released in December 2022 and aims to streamline the approval process for novel TB treatments.
FDA issued final guidance to help sponsors develop drugs for pulmonary tuberculosis. The document replaces an earlier draft and spells out trial design, pediatric, and combination-regimen expectations for a disease still treated with multi-drug courses.
Contents10 sections
Key Takeaways
- FDA’s guidance “Pulmonary Tuberculosis: Developing Drugs for Treatment” is the Revision 1 final text centered in CDER’s anti-infectives review framework.
- Scope is pulmonary TB treatment products under FD&C Act section 505 and related biologic pathways; latent and extrapulmonary TB are out of scope.
- The revision adds detail on nonclinical models, early-phase studies, superiority and noninferiority designs, pediatrics, endpoints, safety, labeling, and an updated NI margin appendix.
- Sponsors should also use FDA’s codevelopment guidance when building multi-investigational regimens.
What is in the FDA pulmonary tuberculosis guidance?
The agency’s PDF guidance on pulmonary tuberculosis drug development states its purpose: help sponsors design clinical programs for investigational drugs used with approved agents or as new regimens that include one or more investigational drugs. The goal is an indication for treatment of pulmonary TB.
FDA notes the text revises and replaces the November 2013 draft of the same name. Revision 1 expands nonclinical and early-phase advice and clarifies how to show efficacy with superiority or noninferiority designs.
What trial design issues does FDA emphasize?
Combination therapy is standard in TB. Sponsors must justify how a new agent contributes inside a regimen. FDA points readers to the separate guidance on codevelopment of two or more new investigational drugs for use in combination. Noninferiority programs need a justified margin; the guidance appendix discusses NI margin reasoning.
Early dialogue matters. The Division of Anti-Infectives Pre-IND page encourages sponsors to share phase 1–2 plans before IND packages harden.
How does FDA treat pediatric and special populations?
The revision updates pediatric inclusion expectations. For pulmonary TB, pediatric extrapolation is generally discussed once adult antimycobacterial activity and dosing are characterized, with PK to support dosing across age groups and an adequate pediatric safety database. Programs should also plan for pregnant populations when nonclinical reproductive data allow.
- Document: Pulmonary Tuberculosis: Developing Drugs for Treatment (Guidance for Industry)
- Center: CDER
- Revision: Revision 1 (finalizes 2013 draft)
- Out of scope: latent TB; extrapulmonary TB
- Companion topic: codevelopment of combination investigational drugs
Why does this matter for TB pipeline sponsors?
Drug-resistant pulmonary TB still needs shorter, safer regimens. Clear FDA expectations on endpoints and NI margins reduce avoidable protocol amendments. Global sponsors should still align with WHO treatment guidelines and other regulators, but U.S. IND and NDA strategy should track this CDER text first.
What WHO burden context sits behind the guidance?
WHO tuberculosis materials keep TB among the world’s leading infectious killers. That public-health backdrop explains why FDA invests detailed guidance even though U.S. case counts are lower than in high-burden countries.
What remains unproven?
Guidance is not a product approval. It does not guarantee that any specific new regimen will meet NI margins or pediatric extrapolation assumptions. Sponsors still need product-specific FDA meeting minutes before locking pivotal protocols.
Related NovaPharma coverage
Frequently Asked Questions
What does FDA’s pulmonary tuberculosis guidance cover?
It gives FDA’s current recommendations for clinical development of investigational drugs for pulmonary TB, including nonclinical models, early-phase studies, superiority or noninferiority trial designs, pediatrics, endpoints, safety, and labeling.
Does the guidance cover latent or extrapulmonary TB?
No. FDA states the guidance does not address development of drugs for latent TB infection or for extrapulmonary TB.
Where should sponsors discuss early TB programs?
FDA encourages early engagement with the Division of Anti-Infectives, including Pre-IND submissions, to align nonclinical, clinical, and combination-regimen plans.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
